Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 18;59(7):e0037421.
doi: 10.1128/JCM.00374-21. Epub 2021 Jun 18.

Comparison of the Quantitative DiaSorin Liaison Antigen Test to Reverse Transcription-PCR for the Diagnosis of COVID-19 in Symptomatic and Asymptomatic Outpatients

Affiliations

Comparison of the Quantitative DiaSorin Liaison Antigen Test to Reverse Transcription-PCR for the Diagnosis of COVID-19 in Symptomatic and Asymptomatic Outpatients

Stefanie Lefever et al. J Clin Microbiol. .

Abstract

We evaluated the quantitative DiaSorin Liaison severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen test in symptomatic and asymptomatic individuals consulting their general practitioners (GPs) during a period of stable intense virus circulation (213/100,000 habitants per day). Leftover reverse transcription-PCR (RT-PCR) positive (n = 204) and negative (n = 210) nasopharyngeal samples were randomly selected among fresh routine samples collected from patients consulting their GPs. Samples were tested on Liaison XL according to the manufacturer's instructions. Equivocal results were considered negative. The overall sensitivity and specificity of the Liaison antigen test compared to RT-PCR were 65.7% (95% confidence interval [CI], 58.9% to 71.9%) and 100% (CI, 97.8% to 100%). Sensitivity in samples with viral loads of ≥105, ≥104, and ≥103 copies/ml were 100% (CI, 96.3% to 100.0%), 96.5% (CI, 91.8% to 98.7%), and 87.4% (CI, 81.3% to 91.5%), respectively. All samples with ≤103 copies/ml were antigen negative. The ratio of antigen concentration to viral load in samples with ≥103 copies/ml was comparable in symptomatic and asymptomatic individuals (P = 0.58). The proportion of RT-PCR-positive participants with a high viral load (≥105 copies/ml) was not significantly higher in symptomatic than in asymptomatic participants (63.9% [CI, 54.9% to 72.0%] versus 51.9% [CI, 41.1% to 62.6%]; P = 0.11), but the proportion of participants with a low viral load (<103 copies/ml) was significantly higher in asymptomatic than in symptomatic RT-PCR-positive participants (35.4% [CI, 25.8% to 46.4%] versus 14.3% [CI, 9.0% to 21.8%]; P < 0.01). Sensitivity and specificity in samples with a viral load of ≥104 copies/ml were 96.5% and 100%. The correlation of antigen concentration with viral load was comparable in symptomatic and asymptomatic individuals.

Keywords: COVID-19 testing; SARS-CoV-2; ambulatory care; antigen; diagnosis; sensitivity and specificity.

PubMed Disclaimer

Figures

FIG 1
FIG 1
RT-PCR results and viral load according to Liaison antigen test results. (A to C) RT-PCR results for the N1 (A) and N2 (B) gene regions and viral loads (C) in samples that were positive and negative in the Liaison antigen test. (D) Correlation of the CT values for the N1 and N2 gene regions in RT-PCR-positive samples.
FIG 2
FIG 2
Quantitative Liaison antigen test results in symptomatic and asymptomatic patients compared to viral load (A) and lowest CT value of the N1 or N2 gene region (B). Vertical lines represent the limit of detection (22 TCID50/ml), cutoff for equivocal result (100 TCID50/ml), cutoff for positive result (200 TCID50/ml), and upper limit of quantification (100,000 TCID50/ml).
FIG 3
FIG 3
Distribution of results for viral load (A) and quantitative Liaison antigen test results (B) in 119 symptomatic and 79 asymptomatic RT-PCR positive patients. Results are ordered from high to low. Horizontal lines represent the limit of detection (22 TCID50/ml), cutoff for equivocal result (100 TCID50/ml), cutoff for positive result (200 TCID50/ml), and upper limit of quantification (100,000 TCID50/ml).

References

    1. World Health Organization. 2020. SARS-CoV-2 antigen-detecting rapid diagnostic tests: an implementation guide. https://www.who.int/publications/i/item/9789240017740
    1. Young S, Taylor SN, Cammarata CL, Roger-Dalbert C, Montano A, Griego-Fullbright C, Burgard C, Fernandez C, Eckert K, Andrews JC, Ren H, Allen J, Ackerman R, Cooper CK. 2020. Clinical evaluation of BD VeritorTM SARS-CoV-2 point-of-care test performance compared to PCR-based testing and versus the Sofia 2 SARS antigen point-of-care test. J Clin Microbiol 17:e02338-20. 10.1128/JCM.02338-20. - DOI - PMC - PubMed
    1. Atkeson A, Droste M, Stock JH, Mina MJ. 2020. Economic benefits of COVID-19 screening tests. medRxiv 10.1101/2020.10.22.20217984. - DOI
    1. Van Elslande J, Houben E, Depypere M, Brackenier A, Desmet S, André E, Van Ranst M, Lagrou K, Vermeersch P. 2020. Diagnostic performance of seven rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients. Clin Microbiol Infect 26:1082–1087. 10.1016/j.cmi.2020.05.023. - DOI - PMC - PubMed
    1. Dinnes J, Deeks JJ, Adriano A, Berhane S, Davenport C, Dittrich S, Emperador D, Takwoingi Y, Cunningham J, Beese S, Dretzke J, Ferrante di Ruffano L, Harris IM, Price MJ, Taylor-Phillips S, Hooft L, Leeflang MM, Spijker R, Van den Bruel A, Cochrane COIVD-19 Diagnostic Test Accuracy Group . 2020. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev 26:CD013705. 10.1002/14651858.CD013705. - DOI - PMC - PubMed

LinkOut - more resources